Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 10, 2025 | June 11, 2025 |
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| SCYNEXIS INCSCYX · Entity 7194 | Director | June 26, 2025 | June 30, 2025 |
| Vericel CorpVCEL · Entity 4481 | Director | October 16, 2024 | October 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,830 |
Reported balance
After 2025-06-10 transaction · row 1
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 35,700 · Balance 152,830 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.92 · Expires 2035-06-10 | Direct | 53,600 |
Reported balance
After 2025-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-10 · Grant · Acquired 53,600 · Balance 53,600 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
SCYNEXIS INC
Report date June 26, 2025 · Filed June 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 70,000 |
Reported balance
After 2025-06-26 transaction · row 1
1 source rowRow 1 · 2025-06-26 · Grant · Acquired 23,000 · Balance 70,000 F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2035-06-25 | Direct | 23,000 |
Reported balance
After 2025-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-26 · Grant · Acquired 23,000 · Balance 23,000 F2: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
F2: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
Vericel Corp
Report date October 16, 2024 · Filed October 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,000 |
Ending reported balance
After 2024-10-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-10-16 · Exercise / conversion · Acquired 5,833 · Balance 16,833 Row 2 · 2024-10-16 · Sale · Disposed 5,833 · Balance 11,000 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2024-10-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-10-16 · Exercise / conversion · Acquired 5,833 · Balance 0 F2: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2024.
F2: These options, representing the right to purchase 17,500 shares, became exercisable in equal monthly installments over a period of one year, beginning on May 2, 2018, contingent upon continued service to the Company.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KERYX BIOPHARMACEUTICALS INC
Report date December 12, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Disposition to issuer · Disposed 27,333 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-12 · Disposition to issuer · Disposed 140,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.
F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 7,796 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 4, 2019 21:01 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001593968-19-000610 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, became exercisable in equal monthly installments, contingent upon continued service to the Company, with the first vesting date on June 4, 2016, which was one month after the date on which the option was granted. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:01 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,500 | $18.02 | $135,129.00 |
DisclosureSEC source: 0001593968-19-000610 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2018. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:01 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 7,500 | $2.76 | $20,700.00 |
DisclosureSEC source: 0001593968-19-000610 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 13:05 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-19-001637 · doc4.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:35 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerStock Option · Derivative | 140,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030884 · doc4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:35 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerCommon Stock | 27,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030884 · doc4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · shares: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · price: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:40 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 6 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-12-12 F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:40 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $10.05 | Not disclosed |
DisclosureSEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 5 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2028-06-30 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:40 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $17.53 | Not disclosed |
DisclosureSEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 4 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2027-06-09 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:40 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $15.26 | Not disclosed |
DisclosureSEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2026-05-26 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:40 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 18,716 | Not disclosed Strike: $12.48 | Not disclosed |
DisclosureSEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,716 Underlying: Common Stock · 18,716 shares Expires 2026-03-31 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:40 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 10,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030948 · doc4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,231 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier"). Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001593968-18-001531 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, became exercisable in equal monthly installments, contingent upon continued service to the Company, with the first vesting date on June 3, 2017, which was one month after the date on which the option was granted. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 8,500 | $17.75 | $150,908.15 |
DisclosureSEC source: 0001593968-18-001531 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2018. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 8,500 | $2.63 | $22,355.00 |
DisclosureSEC source: 0001593968-18-001531 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001593968-18-001169 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 9,000 shares Expires 2027-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 17,500 shares, became exercisable in equal monthly installments, contingent upon continued service to the Company, with the first vesting date on June 3, 2017, which was one month after the date on which the option was granted. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 9,000 | $12.03 | $108,270.00 |
DisclosureSEC source: 0001593968-18-001169 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2018. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 9,000 | $2.63 | $23,670.00 |
DisclosureSEC source: 0001593968-18-001169 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2018 Filed Jul 12, 2018 18:01 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001114220-18-000079 · wf-form4_153143287911219.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-30 F3 · derivative.exercise_date: The 30,000 stock options vest as to one-third on each of June 30, 2019, June 30, 2020 and June 30, 2021. Read SEC document |
| June 30, 2018 Filed Jul 12, 2018 18:01 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001114220-18-000079 · wf-form4_153143287911219.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,333 F1 · shares: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 30, 2019, June 30, 2020 and June 30, 2021. F2 · balance_after: Includes 19,999 shares of restricted stock. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 16:29 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,294 | $21.50 | $49,321.00 |
DisclosureSEC source: 0001179110-18-009059 · edgar.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,440 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:37 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008962 · edgar.xml · derivative · entry 4 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F5 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:37 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008962 · edgar.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 Underlying: Common Stock · 4,356 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gilman's continued service to the Company. F3 · derivative.expiration_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gilman's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:37 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 8,855 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001179110-18-008962 · edgar.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gilman's continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:37 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008962 · edgar.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 16:01 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,334 | $5.12 | $6,830.08 |
DisclosureSEC source: 0001114220-18-000062 · wf-form4_152883365546585.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,333 F1 · shares: Sale of a total of 1,334 shares of common stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017. F2 · balance_after: Includes 9,999 shares of restricted stock. Read SEC document |
| May 29, 2018 Filed May 31, 2018 16:19 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,333 | $5.22 | $6,958.26 |
DisclosureSEC source: 0001114220-18-000059 · wf-form4_152779792701379.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,667 F1 · shares: Sale of a total of 1,333 shares of common stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017. F2 · balance_after: Includes 13,333 shares of restricted stock. Read SEC document |
| May 02, 2018 Filed May 3, 2018 19:28 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001593968-18-000733 · primary_01.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:20 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 19,989 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001209191-18-001738 · doc4.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989 Underlying: Common Stock · 19,989 shares Expires 2028-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:28 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 1,807 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001178253-17-000021 · wf-form4_150714891078360.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,807 Underlying: Common Stock · 1,807 shares Expires 2027-10-02 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:42 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseWarrants (Right to Buy) · Derivative | 400 | $0.01 Strike: $1.55 | $4.00 |
DisclosureSEC source: 0001209191-17-046310 · doc4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock, par value $0.0001 per share · 400 shares Expires 2022-07-25 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:42 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseCommon Stock, par value $0.0001 per share | 800 | $1.24 | $992.00 |
DisclosureSEC source: 0001209191-17-046310 · doc4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,800 Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 19:54 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 2,430 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001178253-17-000012 · wf-form4_149928448463882.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,430 Underlying: Common Stock · 2,430 shares Expires 2027-07-03 Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 15:53 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009442 · edgar.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gilman's continued service to the Company. F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gilman's continued service to the Company. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 15:53 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 11,207 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001179110-17-009442 · edgar.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gilman's continued service to the Company. Read SEC document |
| June 09, 2017 Filed Jun 20, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000899243-17-016752 · doc4.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-09 F3 · derivative.exercise_date: The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020. Read SEC document |
| June 09, 2017 Filed Jun 20, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-016752 · doc4.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020. F2 · balance_after: Includes 16,666 shares of restricted stock. Read SEC document |
| May 03, 2017 Filed May 5, 2017 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001593968-17-000661 · primary_01.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-05-03 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 18:40 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 1,678 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001178253-17-000005 · wf-form4_149133119945040.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,678 Underlying: Common Stock · 1,678 shares Expires 2027-04-03 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 23:16 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 14,499 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001628280-17-000110 · wf-form4_148365820347917.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,499 Underlying: Common Stock · 14,499 shares Expires 2027-01-03 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 23:16 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 1,308 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001628280-17-000108 · wf-form4_148365816904541.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 1,308 shares Expires 2027-01-03 Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 20:17 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 977 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001628280-16-019926 · wf-form4_147561224421998.xml · derivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977 Underlying: Common Stock · 977 shares Expires 2026-10-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.